These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 27621624)

  • 1. Advancements in nano-enabled therapeutics for neuroHIV management.
    Kaushik A; Jayant RD; Nair M
    Int J Nanomedicine; 2016; 11():4317-25. PubMed ID: 27621624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Getting into the brain: Potential of nanotechnology in the management of NeuroAIDS.
    Nair M; Jayant RD; Kaushik A; Sagar V
    Adv Drug Deliv Rev; 2016 Aug; 103():202-217. PubMed ID: 26944096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nano-Medicine as a Newly Emerging Approach to Combat Human Immunodeficiency Virus (HIV).
    Saravanan M; Asmalash T; Gebrekidan A; Gebreegziabiher D; Araya T; Hilekiros H; Barabadi H; Ramanathan K
    Pharm Nanotechnol; 2018; 6(1):17-27. PubMed ID: 29424324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Chronicity of HIV Infection Should Drive the Research Strategy of NeuroHIV Treatment Studies: A Critical Review.
    Gates TM; Cysique LA
    CNS Drugs; 2016 Jan; 30(1):53-69. PubMed ID: 26749584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New hope for eradication of HIV from the body: the role of polymeric nanomedicines in HIV/AIDS pharmacotherapy.
    Lenjisa JL; Woldu MA; Satessa GD
    J Nanobiotechnology; 2014 Mar; 12():9. PubMed ID: 24655921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanomedicines for HIV therapy.
    Siccardi M; Martin P; McDonald TO; Liptrott NJ; Giardiello M; Rannard S; Owen A
    Ther Deliv; 2013 Feb; 4(2):153-6. PubMed ID: 23343155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nano-ART and NeuroAIDS.
    Das MK; Sarma A; Chakraborty T
    Drug Deliv Transl Res; 2016 Oct; 6(5):452-72. PubMed ID: 27137528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanocarriers for brain specific delivery of anti-retro viral drugs: challenges and achievements.
    Varghese NM; Senthil V; Saxena SK
    J Drug Target; 2018 Mar; 26(3):195-207. PubMed ID: 28866957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Smart nanoparticles as targeting platforms for HIV infections.
    Adhikary RR; More P; Banerjee R
    Nanoscale; 2015 May; 7(17):7520-34. PubMed ID: 25874901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting anti-HIV drugs to the CNS.
    Rao KS; Ghorpade A; Labhasetwar V
    Expert Opin Drug Deliv; 2009 Aug; 6(8):771-84. PubMed ID: 19566446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating Nanomedicines: Obstacles and Advancements.
    Swierczewska M; Crist RM; McNeil SE
    Methods Mol Biol; 2018; 1682():3-16. PubMed ID: 29039088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Target Molecules and Delivery Vehicles for Anti-HIV Drugs In vitro and In vivo.
    Bolhassani A
    Curr Pharm Des; 2018; 24(29):3393-3401. PubMed ID: 29886823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel liquid formulation developed to deliver nanomedicine treatment for HIV/AIDS.
    Nanomedicine (Lond); 2010 Jul; 5(5):684. PubMed ID: 20662639
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacologic approaches to HIV-associated neurocognitive disorders.
    Avedissian SN; Dyavar SR; Fox HS; Fletcher CV
    Curr Opin Pharmacol; 2020 Oct; 54():102-108. PubMed ID: 33049585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nano-based drug delivery system: a smart alternative towards eradication of viral sanctuaries in management of NeuroAIDS.
    Aggarwal N; Sachin ; Nabi B; Aggarwal S; Baboota S; Ali J
    Drug Deliv Transl Res; 2022 Jan; 12(1):27-48. PubMed ID: 33486689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interventions for Neurocognitive Dysfunction.
    Ellero J; Lubomski M; Brew B
    Curr HIV/AIDS Rep; 2017 Feb; 14(1):8-16. PubMed ID: 28110422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanomedicine as a non-invasive strategy for drug delivery across the blood brain barrier.
    Tam VH; Sosa C; Liu R; Yao N; Priestley RD
    Int J Pharm; 2016 Dec; 515(1-2):331-342. PubMed ID: 27769885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in brain targeting and drug delivery of anti-HIV therapeutic agents.
    Al-Ghananeem AM; Smith M; Coronel ML; Tran H
    Expert Opin Drug Deliv; 2013 Jul; 10(7):973-85. PubMed ID: 23510097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "Fusion and binding inhibition" key target for HIV-1 treatment and pre-exposure prophylaxis: targets, drug delivery and nanotechnology approaches.
    Malik T; Chauhan G; Rath G; Murthy RS; Goyal AK
    Drug Deliv; 2017 Nov; 24(1):608-621. PubMed ID: 28240046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential pharmacological approaches for the treatment of HIV-1 associated neurocognitive disorders.
    Omeragic A; Kayode O; Hoque MT; Bendayan R
    Fluids Barriers CNS; 2020 Jul; 17(1):42. PubMed ID: 32650790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.